DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2016-03-11

Last Posted Date: 2023-02-08

Lead Sponsor: AbbVie

Target Recruit Count: 499

Registration Number: NCT02706847

Locations: 🇺🇸
AZ Arthritis and Rheum Assoc /ID# 148593, Mesa, Arizona, United States
🇺🇸
NEA Baptist Clinic /ID# 149280, Jonesboro, Arkansas, United States
🇺🇸
New England Research Associates, LLC /ID# 142763, Bridgeport, Connecticut, United States

and more 185 locations

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: adalimumab
Drug: risankizumab
Drug: placebo for risankizumab
Biological: placebo for adalimumab

First Posted Date: 2016-02-29

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 684

Registration Number: NCT02694523

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Phase 3

Completed

Conditions: HCV
Hepatitis C Virus
Chronic Hepatitis C

Interventions: Drug: glecaprevir/pibrentasvir

First Posted Date: 2016-02-26

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT02692703

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Phase 3

Completed

Conditions: Heavy Menstrual Bleeding
Uterine Fibroids

Interventions: Drug: Placebo for Estradiol/Norethindrone Acetate
Drug: Elagolix
Drug: Placebo for Elagolix
Drug: Estradiol/Norethindrone Acetate

First Posted Date: 2016-02-25

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 378

Registration Number: NCT02691494

Locations: 🇺🇸
University of California, Los Angeles /ID# 149760, Los Angeles, California, United States
🇺🇸
Mount Vernon Clinical Res, LLC /ID# 144297, Atlanta, Georgia, United States
🇺🇸
Clinical Trial Investigators /ID# 152470, Tustin, California, United States

and more 102 locations

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

Phase 1

Terminated

Conditions: Bacterial Infections

Interventions: Drug: Dalbavancin

First Posted Date: 2016-02-23

Last Posted Date: 2022-03-29

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT02688790

Locations: 🇺🇸
Children's Mercy Kansas City, Kansas City, Missouri, United States
🇺🇸
Mary Birch Hospital for Women and Newborns, San Diego, California, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

and more 2 locations

A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients

Completed

Conditions: Intestinal Behcet's Disease (BD)

First Posted Date: 2016-02-22

Last Posted Date: 2021-03-22

Lead Sponsor: AbbVie

Target Recruit Count: 59

Registration Number: NCT02687828

Locations: 🇰🇷
Pusan Nat Univ Yangsan Hosp /ID# 169243, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of
🇰🇷
Ajou University Hospital /ID# 147938, Suwon-si, Gyeonggido, Korea, Republic of
🇰🇷
Kyungpook National Univ Hosp /ID# 147937, Daegu, Daegu Gwang Yeogsi, Korea, Republic of

and more 7 locations

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: placebo for risankizumab
Drug: ustekinumab
Drug: risankizumab
Drug: placebo for ustekinumab

First Posted Date: 2016-02-18

Last Posted Date: 2021-08-23

Lead Sponsor: AbbVie

Target Recruit Count: 577

Registration Number: NCT02684357

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: placebo for risankizumab
Drug: risankizumab
Drug: placebo for ustekinumab
Drug: ustekinumab

First Posted Date: 2016-02-18

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 560

Registration Number: NCT02684370

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2016-02-05

Last Posted Date: 2023-04-11

Lead Sponsor: AbbVie

Target Recruit Count: 661

Registration Number: NCT02675426

Locations: 🇪🇸
Hospital Clin Univ San Carlos /ID# 138993, Madrid, Spain
🇺🇸
Houston Institute for Clin Res /ID# 138716, Houston, Texas, United States
🇧🇪
AZ Sint Lucas /ID# 141338, Brugge, Belgium

and more 164 locations

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Rovalpituzumab tesirine

First Posted Date: 2016-02-04

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 342

Registration Number: NCT02674568

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy